Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Bioscience Reports|November 22, 2015
Nucleotide-binding mechanisms in pseudokinasesHenrik M Hammarén, Anniina T Virtanen, Olli SilvennoinenCytokine|April 25, 2018
The regulation of JAKs in cytokine signaling and its breakdown in diseaseHenrik M Hammarén, Anniina T Virtanen, Juuli Raivola, et al.Current Opinion in Chemical Biology|November 11, 2022
Thermal proteome profiling: Insights into protein modifications, associations, and functionsCecile Le Sueur, Henrik M Hammarén, Sindhuja Sridharan, et al.Nature Communications|January 13, 2023
Control of protein stability by post-translational modificationsJi Min Lee, Henrik M Hammarén, Mikhail M Savitski, et al.Nature Communications|December 2, 2022
Protein-Peptide Turnover Profiling reveals the order of PTM addition and removal during protein maturationHenrik M Hammarén, Eva-Maria Geissen, Clement M Potel, et al.Blood Advances|September 21, 2020
JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNsFriederike Pastore, Aishwarya Krishnan, Henrik M Hammarén, et al.Frontiers in Oncology|December 19, 2018
Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase DomainJuuli Raivola, Henrik M Hammarén, Anniina T Virtanen, et al.Proceedings of the National Academy of Sciences of the United States of America|April 1, 2015
ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activationHenrik M Hammarén, Daniela Ungureanu, Jean Grisouard, et al.The Journal of Allergy and Clinical Immunology|August 10, 2018
Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutationsHenrik M Hammarén, Anniina T Virtanen, Bobin George Abraham, et al.ACS Medicinal Chemistry Letters|June 20, 2017
Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule BindersDavid E Puleo, Kaury Kucera, Henrik M Hammarén, et al.Pageof 2